1. Introduction
The management of pulmonary diseases in sheep fattening houses often relies on the administration of antibiotics to sick animals but also to contaminated ones to prevent the spread of the infection. Indeed, it has been shown that early/metaphylactic antibiotic treatments are more efficacious than curative treatments administered only to clinically sick animals [
1,
2]. Due to the high density of animals in fattening houses, tens or hundreds of animals need to be treated during the epidemic stage of disease, which precludes individual administrations of the antibiotics by intramuscular or subcutaneous route.
In such cases, a collective oral treatment via the feed or drinking water is required even if, in the context of a prudent use of antimicrobials in veterinary medicine, mass medication is of major concern [
3]. In the recent EMA (European Medicines Agency) categorization of antibiotics for prudent and responsible use in animals, oral group medications were classified as high risk for resistance selection, the risk being greater for medicated food than for drinking water [
3]. Indeed, delivery of a drug in drinking water is more flexible than in feed. Medicated drinking water can be instantaneously prepared and the doses and volumes easily modulated every day [
4]. However, most of the oral formulations available for sheep were developed for direct administration as a bolus in the animal’s mouth and no or very few data are available on the drug’s solubility and stability in water. Moreover, the drinking water in fattening houses can come from the municipal water supply or from underground water extracted from a well and can have very different chemical properties ranging from acidic to basic and different hardnesses which can impair drug’s solubility. In a recent study by Vandael et al. [
5], 33 out of 52 pig farmers reported some practical problems, such as solubility issues and precipitation, with drinking water medication.
In addition to solubility and stability issues in the pipelines, group medication exhibits additional variability associated with individual drinking behaviors, which can lead to overexposure or underexposure of animals to the antibiotic. In pigs, Soraci et al. [
6] showed that the plasma exposure of animals to fosfomycin varied considerably between pigs after administration in the feed or drinking water and that this interindividual variability, lower for drinking water, could be partly explained by the social rank of the animal. However, apart from ensuring adequate access of the animals to the water, interindividual variability is probably very difficult to manage in the field. Therefore, any factor that might contribute to poor plasma exposure to antibiotics, such as product solubility or dosage regimen, needs to be carefully optimized to limit treatment failures and the selection of antibiotic resistance.
A combination of sulfonamides and diaminopyrimidines has long been used in veterinary medicine to manage bacterial and protozoal infections and is frequently employed to control respiratory infections in cattle and sheep [
7]. These antibiotics have been classified as low risk by EMA [
3] and are considered suitable for first-line treatments in veterinary medicine. Sulfonamides and diaminopyrimidines are considered as primarily bacteriostatic but become synergistic and bactericidal when used in combination by inhibiting different steps of tetrahydrofolate biosynthesis [
8]. Many sulfonamides (sulfadiazine, sulfadimethoxine, sulfamethoxypyridazine, sulfamethoxazole, sulfadoxine or sulfadimidine) are available in combination with trimethoprim (TMP) in veterinary medicine while only sulfamethoxazole is registered in combination with TMP in human medicine. The terminal half-life of TMP is less than one hour in sheep [
9,
10] whereas very different half-lives have been reported for the various sulfonamides. Sulfadiazine or sulfathiazole with half-lives in sheep of 4 h [
10] and 1.1 h [
11] respectively are considered as short-acting sulfonamides while sulfadimethoxine (SDM) with a half-life of 12.5 h in cattle [
12] is a long-acting one. Whatever the pharmacokinetic properties of drugs, most of the formulations registered in animals contain a 5:1 ratio for sulfonamides and TMP, which was originally extrapolated from human medicine even though data on the relevance of this ratio in veterinary species are very sparse. The main advantage of a long half-life is that fluctuations in the concentrations during the dosing interval are low, requiring less frequent administrations, while the drawback can be the delay for plasma concentrations to reach steady-state [
13]. The bioavailability after administration by oral route can also differ, with bioavailabilities ranging from 12 to 68% in dwarf goats for some sulfonamides [
14] and from 44 to 84% in goats for others [
15]. In sheep, the oral bioavailabilities reported for sulfadiazine and sulfamethazine are around 69% [
10] and 58% [
16], respectively. No value for the bioavailability of TMP after oral route in ruminants were found but Shoaf et al. [
17] reported very low concentrations after oral treatment in 12-week old calves.
In this study, we investigated the exposure of sheep to SDM and TMP after administration of the SDM-TMP combination or SDM alone at the recommended doses in the drinking water. We first compared the oral and intravenous pharmacokinetic profiles of the drugs in experimental settings and then assessed, in field conditions, the drug concentrations in the drinking water and in lamb plasma after delivery of the drug via the drinking water. In vitro solubility assays were performed to identify and investigate the factors limiting adequate drug exposure, by comparing the oral pharmacokinetic profiles in pre-ruminating and ruminating lambs, assessing the drug concentrations in the troughs, and by monitoring individual drinking behaviors.
3. Discussion
Although several products containing a combination of sulfonamide and TMP have been registered for oral route in sheep, little if any information is available on their pharmacokinetic properties, especially when administered via the drinking water, which implies that the blood exposure of animals to the drugs after such treatments is uncertain. To promote a rational use of antibiotics and avoid useless antibiotic consumption, a better knowledge is required of the animal’s blood exposure to drugs after treatments via the drinking water.
The first issue with using drinking water to deliver a drug is the drug’s solubility which needs to be very high, considering the very concentrated stock solution required upstream of the metering pump. For many drugs/formulations, no information is available about solubility at the time of registration, even though precipitation can occur in water especially at low temperature, extreme (mainly alkaline) pH, or in hard water. In this study, the low in vitro solubility of one of the drugs, even after addition of a diluent, excluded it from further experiments. A recent review on water medication reported that this problem of solubility in the stock solution could also occur for other antimicrobial drugs [
18]. In our study, one product was soluble at high concentrations for 2 h at +4 °C in the laboratory and the solution seemed homogeneous in the metering pump with no deposit on the first treatment day but eventually a deposit appeared both in the pump and the drinking troughs as the days went by. These observations demonstrate that an apparent solubility at the time of stock solution preparation may not be sufficient to ensure solubility in the pipelines throughout the treatment period. Stability of the drug in the stock solutions is another issue because these solutions are usually prepared once or at most twice a day in farms. Here, SDM seemed to remain stable since the expected concentration was found in the troughs at all sampling times during the treatment with SDM alone.
The need to obtain drug solubility and stability data before administering a new treatment in drinking water is therefore paramount. However, to comply with EMA recommendations, relatively old drugs (sulfonamides, tetracyclines, penicillins, etc.), for which solubility and pharmacokinetics data are usually poor, are preferentially selected for oral medication.
To determine the exposure of animals to SDM-TMP, we first examined the plasma concentration profiles obtained after individual administration of the SDM-TMP combination (Trisulmix
® Liquid for oral administration and Trisulmix
® Injectable for intravenous administration) in experimental settings. The dose ratio of SDM:TMP in these formulations is 5:1, which is the most common. This ratio was first established in human medicine to ensure the greatest synergistic effect on bacteria and the ratio of peak plasma concentrations of sulfamethoxazole:TMP in human patients was thus 20:1 [
19,
20,
21]. To be able to use this same dose ratio in veterinary medicine, the pharmacokinetic profiles of the drugs would need to be similar in animals and humans to preserve the synergistic effect. However, several studies have shown that TMP pharmacokinetics are highly dependent on the species examined. For example, the half-life of TMP is 10–14 h in humans [
22], whereas it is about 35–44 min in sheep [
9,
10]. We also found a similar half-life of 0.47 ± 0.23 h after IV administration. Indeed, TMP is supposed to be extensively metabolized by the liver in cattle and goats [
23]. Being a weak base, TMP can also be trapped in tissues and in the rumen where it can then be degraded by the local microflora. The same mechanisms could also explain the very low bioavailability already observed after oral route in ruminants [
17,
23] and confirmed here in experimental settings. Thus, the very short half-life of TMP suggests that the contribution of TMP as a potentiator of SDM would be very poor in sheep, whatever the route of administration, and the very low oral bioavailability reinforces this drawback when the drug is given orally. In addition, our results indicate that the presence of TMP in the SDM-TMP formulation could decrease the solubility of the product. Indeed, deposits were observed in the pipelines, the expected concentrations of TMP were never attained in the troughs and, more importantly, residual TMP concentrations were observed for several days after the end of treatment in the troughs. This sustained presence of TMP in the ducts could exert selective pressure on the bacterial biofilms formed in the pipelines and favor the selection of antimicrobial resistance in the farm environment. Although SDM exhibited a far better behavior as it rapidly attained the expected concentrations in the troughs and rapidly disappeared from the pipes at the end of the treatment, these concentrations were much more variable when SDM was combined with TMP than when administered alone.
Different pharmacokinetic profiles after oral administration have been reported for sulfonamides in ruminants. Some sulfonamides such as sulfadimidine (=sulfamethazine), sulfanilamide or sulfamerazine have low bioavailabilities by oral route whereas others such as sulfamethoxazole, sulfatroxazole, or sulfadiazine have oral bioavailabilities exceeding 70% in adult goats or calves [
14,
15,
17]. Previous studies have also shown that age and diet can affect the disposition of sulfonamides with, for example, a slight decrease in bioavailability observed in animals fed with grain as compared to animals receiving milk [
17]. In this study, the bioavailability of SDM by oral route was complete for both pre-ruminant and ruminant lambs, implying that the oral route would be suitable for lambs of any age. SDM is reported to have a long half-life in many species, with a half-life of 12.5 h in cattle [
12]. In our study, a similar terminal half-life was found in lambs with averages of 21.0 and 17.3 h after administration by oral and intravenous routes, respectively. This long terminal half-life can decrease the intra-individual variability of SDM concentrations but can also increase the time required to attain the steady-state concentrations [
13]. Considering a half-life of 17 h, an administration once a day and equation 5 [
13], the plasma concentrations of SDM at steady state should have been 1.6-fold higher than the concentrations observed on the 1st day of treatment. Under our conditions, we found a greater difference between the 2nd and 4th days of treatment, the average plasma concentrations in lambs being 2.7-fold higher on the 4th day than on the 2nd day. One explanation could be that the SDM concentrations in drinking troughs were lower than expected on the first days of treatment with the SDM-TMP combination. Another explanation could be that the lambs delayed water consumption and thus antibiotic intake on the 1st day of treatment. Low exposure to SDM during the first days of treatment is not desirable, because efficacy against the pathogens might be delayed and allow the spread of the disease over a longer period. Moreover, underexposure to antibiotics, while being useless to control the pathogens, can promote the selection of resistance. To address this issue of low concentrations at the beginning of treatment, we first tried to improve the supply of SDM to the drinking troughs. As TMP concentrations in drinking troughs were very low, we suspected that TMP precipitates and could at the same time lower the SDM solubility. We thus decided to administer SDM alone, expecting the subsequent solubility and concentrations in the drinking troughs to be closer to those required from the very beginning of the treatment. As the terminal half-life of SDM was quite long, we therefore planned a loading dose (twice the maintenance dose) for the 1st day of treatment. This new dosing regimen led to very similar average plasma concentrations of 38.1 (1st day), 50.2 (2nd day), 49.8 (3rd day), 60.2 (4th day) and 49.0 (5th day) µg/mL, with a 1.3-fold difference between the 1st and 5th day at the population level.
The individual plasma concentrations of SDM in lambs ranged from 1.28 to 98.49 µg/mL (49.8 ± 14.6 µg/mL) during the 5-day treatment. Such high intra- and inter-individual variabilities can result in ineffective treatments or toxicity in some animals with extremely low or high exposures. The measurements of water consumption did not reveal any decrease in consumption in the pens at the start of treatment suggesting that the taste of the drug was accepted by the animals. Individual water consumption by pigs is reported to be influenced by numerous factors including stress, boredom, environmental temperature, disease, feed type and constituents and water flow rates [
18], but in our study, despite the same age, weight, environment, food and health status, the individual consumption varied considerably between the lambs. Soraci et al. [
6] showed that consumption in healthy animals was also dependent on social rank, even if the effect was lower for water than for feed consumption. Here, the estimated individual daily drinking volumes ranged from 0 to 9.8 L implying that the individual daily doses, for a SDM concentration in the drinking troughs of 374 µg/mL, ranged from 0 to 147 mg/kg BW while the targeted one was 37.4 mg/kg BW. These different doses probably explain most of the observed inter-individual variability in plasma concentrations but the time-development of drinking behavior of each lamb, with either frequent or infrequent visits to the troughs, could also accentuate this variability. In pigs, one or two peaks of water consumption were observed over each 24-h period [
18]. We also observed a similar trend with two peaks, mainly during daytime, in the lamb population. However, at the individual level, some lambs behaved very differently, drinking frequently throughout the day for no obvious reason. Under epidemic conditions, the variability between animals can be even higher due to a potential influence of the disease on drinking behavior and additional studies should be carried out to check if sick animals are at least as exposed to drugs as healthy animals. Success of the treatment at the population level will then rely on attaining a defined target value for the relevant pharmacokinetic/pharmacodynamic index, which is dependent both on exposure to the drug and on the MIC of pathogens, in a sufficiently high proportion of the animals within the group. Here, we showed that the synergy of SDM and TMP was lost in sheep, due to the absence of TMP in sheep plasma, and that the efficacy of SDM alone to control pathogenic bacteria should therefore be considered. Unfortunately, most of the published susceptibility data on respiratory pathogens such as
Mannheimia haemolytica and
Pasteurella multocida are provided for the sulfamethoxazole/TMP combination [
24] and very few data are available for sulfonamides alone. In any case, even if adequate exposure to the drug at the population level would control disease spread within the herd, a second-line treatment would be required for a few animals due to unavoidable individual underexposure to the drug.
4. Materials and Methods
4.1. Solubility in Water of Formulations Containing the SDM-TMP Combination or SDM Alone
Solubility in drinking water of two different formulations of SDM-TMP (Trisulmix® Powder and Trisulmix® Liquid, Coophavet, Ancenis, France) and one formulation of SDM alone (Emericid® Sulfadimethoxine, Virbac, Carros, France) was assessed in water with different combinations of pH (5.5, 6.5, 7.5 or 8.5) and hardness (10 °f, 30 °f and 50 °f), representative of those found in sheep fattening houses. A carbonate buffer was first prepared, the pH was then adjusted with HCl 2 M or NaOH 10 M and the hardness with CaCO3 to create the different testing conditions.
Based on the labelled doses of 30 mg/kg BW SDM and 6.5 mg/kg BW TMP for Trisulmix® Powder and Trisulmix® Liquid, the predicted water consumption per animal (1 L/10 kg BW/day) and the pump dilution rate of 10%, the maximum concentration calculated for the different formulation in the metering pump were 17 g of Trisulmix® Powder and 17 mL of Trisulmix® Liquid per liter of water. Based on the labelled dose of 55.68 mg/kg BW for Emericid® Sulfadimethoxine, the predicted water consumption per animal (1 L/10 kg BW/day) and the pump dilution rate of 6%, the maximum concentration calculated for the formulation in the metering pump was 43.2 mL of Emericid® per liter of water.
The solubility of the different formulations was first tested after 2 h at room temperature (RT), then at +4 °C if the product was soluble at RT or at +30 °C if the product was not soluble at RT. For formulations containing the SDM-TMP combination, the experiments were carried out in the presence or not of an organic diluent (Super Diluant Virbac®, Virbac, Carros, France) which is sometimes recommended to increase drug solubility in the dosing pump in sheep fattening houses. For all the tests, the level of product solubility was determined visually. The most soluble formulations were used to determine the pharmacokinetic parameters of SDM and TMP in experimental settings and for the treatment of animals in fattening houses.
4.2. Animals
All the lambs were Lacaune or Lacaune crossbreds supplied by the agricultural cooperative Arterris (Castelnaudary, France). The experimental protocols were authorized by the French Ministry of Research under the number #4637_2016032217062253 on 11 May 2017 for the laboratory experiment done at the INTHERES animal facility and the number #11919_2017102415533573 on 26 June 2018 for the two experiments conducted in a sheep fattening house managed by the agricultural cooperative Arterris.
4.3. Pharmacokinetic Parameters of SDM and TMP in Experimental Settings
Eight, 1-month-old lambs (4 males and 4 females) were weaned on the day of their arrival in the animal facility as they would have been on entering the fattening house. They were fed ad libitum with a starter feed for 10 days and then with a maintenance feed, these feeds being the same as those used in the fattening house and free of antibiotics. The lambs also had free access to water and straw. They received one dose of diclazuril on arrival and another one 10 days later (Vecoxan® 2.5 mg/mL, 1 mg/kg BW, Elanco, Sèvres, France) to reduce the risks of coccidiosis. Six days after their arrival and weaning, the 8 lambs (13.5 ± 1.8 kg BW) received an oral bolus of SDM-TMP (Trisulmix® Liquid, 24.7 mg/kg BW SDM + 5.3 mg kg BW TMP). Blood samples were collected just before drug administration and 0.25, 0.75, 1.5, 2, 2.5, 4, 6, 9, 24, 30, 48 and 72 h after administration. Seven days later, the lambs (15.1 ± 2.1 kg BW) received an intravenous bolus of SDM-TMP (Trisulmix® Injectable, 24.7 mg/kg BW SDM + 5.3 mg/kg BW TMP, Coophavet, Ancenis, France). Blood samples were collected just before administration and 0.08, 0.25, 0.5, 1, 2, 4, 6, 9, 24, 30, 48 and 72 h after administration, to determine the oral bioavailability of SDM and TMP. Finally, again seven days later (that is 14 days after the first oral administration and 20 days after weaning), the oral administration was repeated on the same lambs (17.6 ± 2.8 kg BW) to determine whether the pharmacokinetics of SDM and TMP could be influenced by the lamb’s ruminal status. Each 2 mL blood sample was taken from one jugular vein (for the intravenous administration, jugular opposed to the one used for the administration) and collected in heparinized tubes. The samples were then centrifuged at 3000× g for 10 min at +4 °C, and the collected plasma stored at −20 °C before assay.
4.4. Individual Pharmacokinetics of SDM and TMP in Combination and Individual Water Consumption in Fattening Houses
Two hundred lambs, around 40 days old, were dosed with Trisulmix® Liquid (37.4 mg/kg BW/24 h SDM + 8.0 mg/kg BW/24 h TMP) for 4 days via drinking water. A sufficient volume of stock solution was prepared once a day in the metering pump to supply the drug in the pipelines over 24 h. The metering pump was set at 4%. Dissolution of the SDM-TMP was facilitated by adding Super Diluant Virbac® to the metering pump (Trisulmix® Liquid:Super Diluant Virbac®, 1:1). The treated lambs were allocated to two pens of 100 lambs (50 males and 50 females), each pen being equipped with two constant-level drinking troughs. The lambs in pen 1 were neither sampled nor handled, in order to assess water consumption before, during and after treatment with limited human influence, while the lambs in pen 2 were sampled several times to quantify the plasma SDM and TMP concentrations. The individual water consumption was determined in real time for all the lambs in pens 1 and 2 from three days before treatment to three days after the end of treatment using water meters connected to the drinking troughs which detected the RFID chip in the lamb ear tags. Lamb access to the drinking troughs was adapted to allow only one lamb at a time. Water samples were taken throughout the duration of treatment from the two drinking troughs in each of the two pens (n = 4) before, and 1 h, 4 h (except on the 4th day), 8 h and 12 h (except on the 3rd day) after the renewal of the treatment in the metering pump each morning, and from one drinking trough in each of the two pens once per day for 4 days after the treatment. The water samples were collected in vials stored at +4 °C until the assays. The lambs in pen 2 were divided into 4 batches of 25 lambs. One blood sample per lamb was taken on the 2nd and 3rd days of treatment and four blood samples per lamb, taken between 07:30 and 18:30 at 12 sampling times with 25 sampled lambs at each time, were obtained on the 4th day of treatment. The blood samples were collected in heparinized tubes, centrifuged at 3000× g for 10 min at +4 °C, and the collected plasma stored at −20 °C.
4.5. Individual Pharmacokinetics of SDM Alone in Fattening Houses
The number and characteristics of the treated animals were identical to those in the first experiment. This time, the 200 lambs were dosed with Emericid® Sulfadimethoxine (55.68 mg/kg BW SDM on the 1st day and 27.84 mg/kg BW/24 h SDM from the 2nd to 5th day) for 5 days via the drinking water. A sufficient volume of stock solution was prepared once a day in the metering pump to supply the drug in the pipelines over 24 h. The pump was set at 10%. Water samples were taken throughout the duration of treatment: from the metering pump before and 3 h after renewal of the treatment, from the drinking troughs several times during the treatment, twice on the day the treatment was stopped and once every two days for 5 days after the treatment. One blood sample was obtained from the lambs of batch 1 (n = 50) in pen 2 on the 1st, 3rd and 4th days of treatment and the 3rd day (Day 8) after the end of treatment. One blood sample was obtained from the lambs of batch 2 (n = 50) in pen 2 on the 2nd, 3rd and 5th days of treatment and the 5th day (Day 10) after the end of treatment. The plasma and water samples were processed as previously described.
4.6. SDM and TMP Assays
4.6.1. SDM and TMP Assays in Plasma in the Laboratory Experiment
SDM and TMP plasma concentrations were determined by LC/MS with an Acquity ultra performance liquid chromatography (UPLC®) coupled to a Xevo® triple quadrupole mass spectrometer (Waters, Milford, MA, USA). Plasma samples (50 µL) were spiked with 150 µL of IS (Internal Standard) sulfapyridine at 0.1 µg/mL in trichloracetic acid (TCA 5%) and centrifuged for 10 min, at 20,000× g and +4 °C. The analytes were separated on a C18 column (Cortecs UPLC C18+, 2.1 × 50 mm, 1.6 µm, Waters) with an H2O, 0.1% HCOOH/AcN gradient elution (t(0 min): 10% AcN, t(0–2 min): 60% AcN ; t(2–2.10 min): 10% AcN ; t(2.10–3 min): 10% AcN). Samples were detected by multiple reactions monitoring (MRM) with a positive electrospray ionization. The MRM transitions monitored were m/z: 250 > 156, m/z: 291 > 230 and m/z: 311 > 108 for sulfapyridine, TMP and SDM, respectively, with collision energies of 16, 24 and 32 eV. The retention times were 1.38, 0.79 and 0.76 for SDM, TMP and IS, respectively. The performance of the method was checked in terms of linearity, inter- and intra-day precision and accuracy, and sensitivity. Six calibration points containing SDM and TMP at concentrations ranging from 0.01 to 5 µg/mL for TMP and from 0.25 to 50 µg/mL for SDM were extracted and assayed over three days. Both linear (Y = aX + b) and quadratic (Y = aX2 + bX + c) models were tested with 1, 1/X and 1/X2 (X = nominal concentration) weightings with these resulting calibration curves. Three approaches were evaluated to select the best model of calibration: (1) the inspection of the residual distribution plotting against nominal concentrations, (2) the lack-of-fit test to check the goodness-of-fit of the model, and (3) the calculation of the relative concentration residuals (RCR%) between the nominal concentration and the concentration obtained with the model, which should be lower than ± 15%. The best calibration fit was obtained with a quadratic model weighted by 1/X2 (X = concentration) for both molecules with RCR% were lower than 15% for all concentrations. The LOQ (limit of quantification) was evaluated with five replicates of plasma samples spiked at 0.25 µg/mL for SDM and 0.01 µg/mL for TMP. They were set as the lowest concentration level of the calibration curve that can be quantified with an acceptable repeatability and accuracy (CV% lower than 20% and accuracy range 80–120%). The accuracies and the intra- and inter-day precisions of the method were evaluated with five replicates of three quality control (QC) samples at three concentration levels (0.025, 0.25 and 2.5 µg/mL for TMP and 0.25, 2.5 and 25 µg/mL for SDM) over three days. Intra and inter-day precision were expressed with coefficient of variation percent (CV%) and calculated with an ANOVA. The intra-day CV% precision was below 11% and 8% and the inter-day CV% precisions were below 19% and 18% for TMP and SDM, respectively. The accuracies ranged from 104% to 121% for TMP, and from 81% to 93% for SDM.
4.6.2. SDM and TMP Assays in Plasma and Drinking Water in the Field Experiments
As a very low level of TMP was detected in the plasma with the previous method and during the previous experiment, and SDM response in the field experiment saturated the MS signal with the previous method, a LC/UV method was developed solely for SDM in plasma. This method using higher concentration levels was also adapted to quantify TMP and SDM in water.
Briefly, SDM and TMP were determined by LC/UV with an Acquity ultra performance liquid chromatography (UPLC®) coupled to a diode array detector (Waters, Milford, MA, USA). The analytes were detected at 270 nm and were eluted under the same conditions as described for the laboratory experiment. SDM was extracted from plasma (100 µL) with 300 µL of IS sulfapyridine at 10 µg/mL diluted in TCA 5% and centrifuged for 10 min, at 20,000× g and +4 °C. The performance of the method was evaluated with a calibration ranging from 1 to 500 µg/mL using a linear model weighted by 1/X and three QC samples (3, 30 and 300 µg/mL). The accuracy ranged from 83% to 104% and intra-day CV% precision was below 13% and inter-day CV% precision was below 14%. The LOQ was set at 1 µg/mL with an intra-day CV precision of 6% and an accuracy of 106%. In water, 100 µL of samples were directly diluted with 300 µL of TCA 5%. As the run took only 3 min, all samples were processed on the same day. The calibration curve ranged from 5 to 1000 µg/mL and from 0.5 to 100 µg/mL for SDM and TMP, respectively.
4.7. Pharmacokinetic and Statistical Analyses
For the laboratory experiment, the non-compartmental analysis was conducted with Phoenix
® software (Phoenix, WinNonlin 64, NLME 1.6, Certara L. P., Pharsight, St-Louis, MO, USA). As (i) the clearance after the intravenous administration was higher than the apparent clearance after the oral administrations and (ii) we cannot exclude a carryover effect between the different administrations, the bioavailabilities by oral route were corrected by addition of the terminal half-life term for each route of administration in the calculation [
25]. The bioavailabilities by oral route were thus determined with Equation (1):
where AUC
oral and AUC
iv are the Area Under Curve from time 0 extrapolated to infinite time after oral and intravenous administrations, t
1/2, iv and t
1/2, oral are the terminal half-life after intravenous and oral administrations, and Dose
iv and Dose
oral are the actual dose administered by intravenous and oral route.
The influence of ruminal status on the SDM pharmacokinetic parameters after an oral administration was analyzed by a non-parametric test (Wilcoxon test) with R® software (R 3.4.3, R Development Core Team, Vienna, Austria).